FY2024 EPS Estimates for Fulcrum Therapeutics, Inc. Boosted by Analyst (NASDAQ:FULC)

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for Fulcrum Therapeutics in a research note issued on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings of ($0.32) per share for the year, up from their prior estimate of ($0.43). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.48) per share. Leerink Partnrs also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.31) EPS, Q2 2025 earnings at ($0.30) EPS, Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.17) EPS and FY2026 earnings at ($1.06) EPS.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, July 31st. The company reported $0.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.93. Fulcrum Therapeutics had a negative return on equity of 8.28% and a negative net margin of 3,470.05%. The business had revenue of $80.00 million during the quarter, compared to analysts’ expectations of $80.00 million. During the same quarter in the previous year, the business earned ($0.38) EPS.

A number of other analysts have also recently weighed in on the stock. HC Wainwright cut shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $17.00 to $4.00 in a research report on Friday, September 13th. Cantor Fitzgerald lowered Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. Stifel Nicolaus downgraded Fulcrum Therapeutics from a “buy” rating to a “hold” rating and dropped their target price for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $10.00 to $2.00 in a report on Thursday, September 12th. Finally, Leerink Partners reiterated a “market perform” rating and set a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Stock Up 9.7 %

FULC opened at $3.49 on Monday. Fulcrum Therapeutics has a 52-week low of $2.87 and a 52-week high of $13.70. The company has a 50 day moving average of $8.29 and a two-hundred day moving average of $8.16. The company has a market cap of $216.92 million, a P/E ratio of -2.18 and a beta of 2.23.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FULC. National Bank of Canada FI lifted its holdings in Fulcrum Therapeutics by 869.6% during the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after buying an additional 4,000 shares during the last quarter. Capstone Investment Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter valued at approximately $68,000. Profund Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics during the second quarter worth $68,000. Renaissance Technologies LLC bought a new position in shares of Fulcrum Therapeutics in the 2nd quarter worth about $82,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Fulcrum Therapeutics by 66.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after buying an additional 4,766 shares during the period. 89.83% of the stock is currently owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.